: iStockAnalyst.com Symbols Feed

Penwest Shareholders Want Liquidation

Wed, 04 Mar 2009 17:05:00 GMT

Penwest Pharmaceuticals (NASDAQ: PPCO) shares are trading near their 52-week lows and some investors are growing restless. Tang Capital and Perceptive Life Sciences are two such shareholders that own a combined 40 percent of the troubled company. The investors expressed serious concerns about Penwest’s direction and believe the company should be liquidated to unlock value. In a letter to the board, Tang Capital and Perceptive Life Sciences wrote: We write to express serious concerns about the current direction of Penwest in the hope that you will take[More...]

Penwest Shareholders Demand Change

Mon, 12 Jan 2009 15:11:00 GMT

Penwest Pharmaceuticals (NDAQ: PPCO) may see some changes during the next annual meeting after a large shareholder proposed a new slate of directors for the board. Perceptive Life Sciences, Tang Capital Partners, and their affiliates collectively own 37.5% of the pharmaceutical company and nominated Joseph Edelman, Keven Tang, and Andrew Levin to the board at the 2009 annual meeting. Investors should be careful before they vote in the new board members, however. Some rhetoric contained within a Schedule 13D filing with the SEC raises some questions. The funds commented: While we strongly believe that changes to the board of directors are in the best interest of all shareholders of the company, … (we) may receive unique benefits if the nominees set forth herein are elected to the board. Such unique benefit[More...]

Quiet Day

Wed, 11 Jun 2008 15:51:02 GMT

Good morning. We're set for a positive open helped mostly by strength in overseas markets. Overall, it's a relatively quiet day so far with focus only on interest rates concerns and rising oil prices.[More...]

This Week's Insider Buys - Apr 6 2008 1:39PM

Sun, 06 Apr 2008 17:34:13 GMT

Here are the insider purchases of over $1 million[More...]

Earnings Summary: Wednesday, March 12, 2008

Thu, 13 Mar 2008 06:13:37 GMT

Ticker: JMP,GNTA,IRN,WX,VM,ALFA,QLTY,AMIE,VOL,PPCO,ANH,STAN,WON,END,ENZ,RAVN,DCGN,NGAS,SGXP,AFCE,CGPI,CYTX,EVOL,GDP,GYMB,HOTT,JAS,JASO,LL,MHGC,MW,NP,PRSC,TBSI,TLB,TRK,VSE,AERG,CODI,FSIN,GLBC,HRLY,MDZ,MED,SUSS,GPOR,SIGM,CADX,ARYX,GSAT,BMTI[More...]

This Week's Insider Buys - Mar 8 2008 2:16PM

Sat, 08 Mar 2008 18:10:49 GMT

This is the largest list to date..XTL Biopharmaceuticals Ltd (XTLB)- $5,127,000Grubb & Ellis Co (GBE)- $4,778,000Zymogenetics Inc (ZGEN)-$ 3,255,000MF Global Ltd (MF)- $3,158,000General Electric Co (GE)-$ 3,008,000Allis Chalmers Energy Inc (ALY) - $2,855,000Penwest Pharmaceuticals Co (PPCO)- $ 2,427,000Enterprise GP Holdings L P (EPE) - $1,893,000American Financial Group Inc New (AFG)-$1,843,000eLoyalty Corp (ELOY)- $ 1,766,000[More...]

The Week's Insider Buys - Feb 9 2008 11:11PM

Sun, 10 Feb 2008 03:05:37 GMT

Barnes & Noble Inc (BKS) = $9,935,860[More...]

NASDAQ Technical Picture - Inside Day - Aug 28 2007 3:53AM

Tue, 28 Aug 2007 07:47:38 GMT

A low volume inside day could be NR7 (price and volume contraction before expansion).[More...]

Penwest Reports Second Quarter 2009 Financial Results

Fri, 07 Aug 2009 11:56:00 GMT

Penwest Pharmaceuticals Co. today reported its financial results for the second quarter of 2009. Compared with the second quarter of 2008, revenues increased sharply, operating expenses decreased by 11% and the Company's net loss was reduced significantly to $2.1 million, or $0.07 per share.[More...]

Penwest Second Quarter 2009 Financial Results Conference Call

Wed, 29 Jul 2009 20:11:00 GMT

Penwest Pharmaceuticals Co. will conduct a conference call on Friday, August 7, at 11:00 a.m. EDT to review its financial results for the second quarter of 2009, which will be released earlier that day. Operational developments and financial outlook will also be discussed on the call.[More...]

Penwest Announces Results of Phase Ib Trial of A0001

Thu, 16 Jul 2009 11:55:00 GMT

Penwest Pharmaceuticals Co. today announced the results of its Phase Ib clinical trial of A0001, a compound the Company is developing for the treatment of mitochondrial diseases. Drs. Amale Hawi, Senior Vice President, Pharmaceutical Development, and Thomas Sciascia, Senior Vice President & Chief Medical Officer, will be presenting these results at the Friedreich's Ataxia Therapeutics Meeting on Friday, July 17, 2009, in Philadelphia, PA.[More...]

Penwest Announces That the Results of Its Annual Meeting Have Been Certified

Wed, 24 Jun 2009 20:25:00 GMT

Penwest Pharmaceuticals Co. today announced that IVS Associates, Inc., the independent inspector of election for the Company's Annual Meeting of Shareholders, held on June 10, 2009, has certified the results of the meeting.[More...]

Penwest Enters Into Third Research and Development Agreement With Otsuka Pharmaceutical

Wed, 17 Jun 2009 13:48:00 GMT

DANBURY, Conn., June 17, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it has signed its third research and development agreement with Otsuka Pharmaceutical Co., Ltd. of Japan to develop a formulation of an undisclosed Otsuka compound utilizing Penwest's TIMERx(r) drug delivery technology.
Under the terms of the agreement, Penwest will receive undisclosed fees and payments.
Jennifer L. Good, Penwest's President and CEO, said, "We are very pleased to have signed our third research and development agreement with Otsuka.

[More...]

Shareholders Elect Tang Capital and Perceptive Nominees and Approve Shareholder Resolution

Wed, 10 Jun 2009 19:04:00 GMT

Tang Capital Partners, LP and Perceptive Life Sciences Master Fund Ltd. today announced that, based on voting estimates from their proxy solicitation firm, shareholders have elected two nominees of Tang Capital and Perceptive as new directors of Penwest Pharmaceuticals Co. (NASDAQ:PPCO). In addition, Tang Capital and Perceptive’s advisory shareholder resolution regarding the winding down of substantially all of the Company’s operations was approved. In both cases, an overwhelming majority of votes cast were voted in favor of the Tang Capital and Perceptive proposals.[More...]

Penwest Announces Preliminary Vote Count At Annual Meeting

Wed, 10 Jun 2009 17:37:00 GMT

Penwest Pharmaceuticals Co. today announced the preliminary results of its Annual Meeting of Shareholders, which was held today.[More...]

Penwest Urges Shareholders to Vote the White Proxy Card Today and Reject Dissident Proposals and Nominees At Wednesday's Annual Meeting

Tue, 09 Jun 2009 13:56:00 GMT

In an open letter to shareholders leading up to the Company's annual meeting to be held this Wednesday, June 10, 2009, Penwest Pharmaceuticals Co. urges shareholders to vote 'FOR' Penwest's director nominees on the WHITE proxy card and 'AGAINST' the proposals put forth by Tang Capital and Perceptive Life Sciences. Shareholders who have voted the dissidents' gold proxy card can still reconsider and vote for value on the Company's WHITE card.[More...]

Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(R) ER in Canada, Australia and New Zealand; Agreement Demonstrates Value of OPANA ER in Markets Outside U.S.

Tue, 09 Jun 2009 11:57:00 GMT

DANBURY, Conn., CHADDS FORD, Pa., and ALISO VIEJO, Calif., June 9, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO), Endo Pharmaceuticals (Nasdaq:ENDP) and Valeant Pharmaceuticals (NYSE:VRX) today announced that Endo has signed an exclusive license with Valeant allowing it to market OPANA ER in Canada, Australia and New Zealand.
OPANA ER, the extended release formulation of oxymorphone, was jointly developed by Penwest and Endo.
This agreement is the first one resulting from the collaborative work Penwest and Endo began late last year to license OPANA ER in territories outside the U.S. Under the terms of the collaboration agreement between Penwest and Endo, the two companies have agreed to share equally in the proceeds received from Valeant for OPANA ER under the terms of the licensing agreement.

[More...]

Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand

Tue, 09 Jun 2009 11:26:00 GMT

Penwest Pharmaceuticals Co. , Endo Pharmaceuticals and Valeant Pharmaceuticals today announced that Endo has signed an exclusive license with Valeant allowing it to market OPANA ER in Canada, Australia and New Zealand. OPANA ER, the extended release formulation of oxymorphone, was jointly developed by Penwest and Endo.[More...]